EdiShorts

When Care Is Out of Reach: Last-Mile Rural Healthcare and the Price of Cancer Drugs

IssueOctober 2026
PaperGS Paper 2
SubjectSociety & Social Issues
Read time3 min

Why in News: Two stories in October 2026 exposed gaps in access to healthcare. In Gumla, Jharkhand, a woman in labour was carried about a kilometre on a bamboo-pole “bahangi” because rain-damaged roads stopped the ambulance. And an editorial on 30 October argued that “affordable cancer care needs more than price caps”, after the government moved to regulate trade margins on non-scheduled cancer drugs — capping the sellers’ mark-up at 30% over the price to stockists, where intermediaries had been adding as much as 170%.

The Rural Last Mile

  • Distance and terrain: villages in hilly, forested and flood-prone areas lack all-weather roads; ambulances (108/102 services) cannot reach.
  • Shortfalls: Rural Health Statistics show large gaps in specialists at Community Health Centres; Primary Health Centres often lack doctors.
  • Solutions in use: bike and boat ambulances, maternity waiting homes near facilities, ASHAs for early registration, telemedicine (eSanjeevani), and PMGSY roads.

The Cancer Drug Pricing Problem

  • India records about 15 lakh new cancer cases a year; costs push families into poverty.
  • Trade margin rationalisation regulates only the distribution chain; manufacturer prices — especially of patented drugs with no generic competition — remain high (the monthly cost of one breast-cancer drug reportedly rose from ₹58,000 to ₹78,000 despite caps).
  • Risks: artificial discounts distorting markets; supply disruption in remote areas; hospitals shifting costs to room rent and consumables.

What Works Better

  • Pooled procurement and price negotiation (as Tamil Nadu’s and Rajasthan’s medical services corporations do), compulsory licensing or voluntary licences for key patented drugs, and promotion of biosimilars.
  • Day-care cancer centres in district hospitals (Budget 2025 targeted 200 in 2025–26) and population-based screening for oral, breast and cervical cancers.
  • Insurance coverage under PM-JAY packages; Jan Aushadhi generic stores.

Static Background — Drug Pricing and Rural Health

  • National Pharmaceutical Pricing Authority (NPPA, 1997): fixes ceiling prices of scheduled drugs (in the National List of Essential Medicines) under the Drugs (Prices Control) Order, 2013 (under the Essential Commodities Act).
  • Non-scheduled drugs: prices can rise up to 10% a year; trade margin rationalisation was first piloted on 42 cancer drugs in 2019.
  • Indian Patents Act, 1970: Section 3(d) blocks “evergreening” (Novartis v. Union of India, 2013 — Glivec); compulsory licence under Section 84 (Natco–Bayer, 2012, for Nexavar).
  • Indian Public Health Standards (IPHS, 2022) prescribe staffing and services; three-tier rural network: Sub-Health Centre (5,000 population in plains), PHC (30,000) and CHC (1.2 lakh).
  • Ayushman Bharat (2018): PM-JAY (₹5 lakh cover per family) and Ayushman Arogya Mandirs (primary care).
FacilityPopulation norm (plains)
Sub-Health Centre5,000
Primary Health Centre30,000
Community Health Centre1,20,000

Exam Angle — Prelims & Mains

  • UPSC PYQ Link: Mains GS-2 has asked about universal health coverage and the Ayushman Bharat scheme; Prelims on Section 3(d) and compulsory licensing.
  • Practice Mains Question (GS Paper 2, 15 marks, 250 words): Price controls alone cannot make cancer care affordable. Discuss a comprehensive strategy, including procurement, patents and the public health system.
  • Prelims Angle: NPPA, DPCO and patent provisions.
    • Practice Prelims MCQ 1: Consider the following statements:
      1. The National Pharmaceutical Pricing Authority fixes ceiling prices of scheduled drugs.
      2. Section 3(d) of the Patents Act, 1970 prevents patents on new forms of known substances unless they show enhanced efficacy.
      3. India has never issued a compulsory licence for a patented medicine.
      Which of the statements given above are correct?
      (A) 1 and 2 only
      (B) 2 and 3 only
      (C) 1 and 3 only
      (D) 1, 2 and 3
      Show answer
      Answer: (A) 1 and 2 only — Statement 1 is CORRECT and Statement 2 is CORRECT. Statement 3 is INCORRECT — India granted a compulsory licence to Natco for Bayer’s sorafenib (Nexavar) in 2012.
    • Practice Prelims MCQ 2: In plain areas, a Primary Health Centre is meant to serve a population of about:
      (A) 5,000
      (B) 30,000
      (C) 80,000
      (D) 1,20,000
      Show answer
      Answer: (B) — A PHC covers about 30,000 in plains (20,000 in hilly and tribal areas).

More Society & Social Issues from October 2026

Written by the EdiShorts editorial team from official and public sources. Check the latest position before quoting figures in the exam.